Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics

Background The therapeutic response to disease-modifying antirheumatic drugs (DMARDs) remains relatively low in psoriatic arthritis (PsA), leading to delayed disease control and frequent treatment switches. Predictive biomarkers may enable personalized treatment and earlier dise…

Criar conta gratuita para acessar o conteúdo completo